Favorable prognosis of breast cancer brain metastases patients with limited intracranial and extracranial metastatic lesions

Table 3 Multivariable cox proportional hazards model for overall survival

Variable	HR	95% CI	P value
GPA
0.0–1.0	1		< 0.001
1.5–2.0	0.63	0.48–0.84	0.002
2.5–3.0	0.35	0.23–0.53	< 0.001
3.5–4.0	0.17	0.08–0.36	< 0.001
Number of metastatic lesions
> 5	1
≤ 5	0.55	0.43–0.72	< 0.001
Salvage local therapy
No	1
Yes	0.58	0.41–0.83	0.003
Chemotherapy
No	1		< 0.001
Yes	0.24	0.17–0.33	< 0.001
Missing	0.40	0.25–0.64	< 0.001
Anti-HER2 therapy
HER2+ with anti-HER2 therapy	1		0.030
Her2+ without anti-HER2 therapy	1.49	1.01–2.20	0.047
HER2−	0.84	0.61–1.16	0.297
Endocrine therapy
HR+ with endocrine therapy	1		< 0.001
HR+ without endocrine therapy	2.88	2.03–4.06	< 0.001
HR negative	2.87	2.02–4.09	< 0.001

HR hormone receptor (estrogen and/or progesterone receptors); HER2 human epidermal receptor 2

ISSN: 1748-717X